Lendrem BC

Lendrem DW

By quickly clearing the development pipeline of failing or marginal products, fast-fail strategies release resources to focus on more promising molecules. The Quick-Kill model of drug development demonstrates that fast-fail strategies will: (1) reduce the expected time to market; (2) reduce expected R&amp;D costs; and (3) increase R&amp;D productivity. This paper outlines the model and demonstrates the impact of fast-fail strategies. The model is illustrated with costs and risks data from pharmaceutical and biopharmaceutical companies

Torching the Haystack: Modelling fast-fail strategies in drug development

Abstract

Similar works

Full text

Available Versions

Newcastle University E-Prints